Description

Lynparza For Sale

What is Lynparza?

Lynparza is a targeted cancer medicine used to treat specific types of ovarian cancer, breast cancer, fallopian tube cancer,  pancreatic cancer, prostate cancer, and peritoneal cancer. Lynparza is often used if your cancer has a specific genetic marker, including BRAC1, BRCA2, HRR, and HER2-negative. Your doctor will test you for this gene. Lynparza For Sale

Lynparza (olaparib) is a tablet that is usually taken twice daily, with or without food.

Lynparza was first FDA-approved in 2014 for advanced ovarian cancer.

How does Lynparza work?

PARP is a protein that helps damaged cells to repair themselves, including some cancer cells. If the cells are not repaired, then the cells die.  Some cancer cells rely on PARP to repair their DNA so they can continue dividing. Lynparza is from a group of medicines called PARP inhibitors (poly (ADP-ribose) polymerase inhibitors). Lynparza works by blocking PARP, which means the cancer cells are no longer able to repair themselves and so die.  Buy Lynparza For Sale Online

What is Lynparza used for?

Lynparza is FDA-approved to treat specific types of cancer.

BRCA-mutated Advanced Ovarian cancer

• first-line maintenance treatment,
• adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer,
• who are in complete or partial response to first-line platinum-based chemotherapy.
• patients should be selected based on an FDA-approved companion diagnostic for this medicine.

 HRD-positive Advanced Ovarian Cancer

• first-line maintenance treatment in combination with bevacizumab
• adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are an incomplete or partial response to first-line platinum-based chemotherapy
• Cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability
• patients should be selected based on an FDA-approved companion diagnostic for this medicine.

Recurrent Ovarian Cancer

• maintenance treatment
• adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Lynparza For Sale

Germline BRCA-mutated HER2-negative High-Risk Early Breast Cancer

• adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy
• patients should be selected based on an FDA-approved companion diagnostic for this medicine.